Accessible, highly scalable single-cell
technology expands Illumina's multiomics
capabilities
SAN
DIEGO, July 9, 2024 /PRNewswire/ -- Illumina,
Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and
array-based technologies, announced that effective today it has
acquired Fluent BioSciences, developer of an emerging and highly
differentiated single-cell technology.
"The addition of Fluent BioSciences to Illumina will provide
significant and new capabilities to our customers in a key growth
area and advances our multiomics growth strategy," said
Steven Barnard, chief technology
officer of Illumina. "Single-cell research opens doors to new areas
of discovery, and Fluent's innovative, accessible, and flexible
single-cell method will accelerate our ability to deliver full
multiomics solutions for our customers."
Fluent's single-cell analysis technology eliminates the need for
complex, expensive instrumentation and microfluidic consumables.
This novel approach removes many of the barriers and limitations of
current methods, making single-cell analysis accessible for a
broader set of customers, and catalyzing new experiments enabled by
the ability to perform that assay at the point of sample
collection. Fluent's latest release, PIPseq™ V, delivers
exceptional performance, with the ability to detect cell types
often missed with current methods, and the highest scalability,
capable of processing a range from 100 cells up to 1 million.
Fluent's unique technology combined with Illumina's leading
sequencing and informatics solutions including Partek Flow, which
enables single-cell multiomic analysis, will provide customers with
a complete solution and single point of support so that researchers
can advance discovery faster and more economically.
The Fluent team will join Illumina, and PIPseq V will be
integrated into Illumina's product portfolio. The company plans to
build on Fluent's technology to develop full end-to-end solutions
for single-cell analysis.
Illumina will remain an open NGS platform and is committed to
maintaining and supporting its existing single-cell partnerships.
"Our goal is to continue to develop the sequencing eco-system and
support the best multiomics solutions like single-cell analysis,"
Barnard said. "We want customers to have the flexibility to adopt
the tools that best fit their needs."
The acquisition closed on July 9,
2024, and has been funded with cash on hand.
Use of forward-looking statements
This release contains forward-looking statements that involve
risks and uncertainties. Examples of forward-looking statements
include, but are not limited to, statements we make regarding our
expectations for the utility and success of Fluent's products and
the integration of Fluent's technology and products into our
portfolio. These forward-looking statements are based on our
expectations as of the date of this release and may differ
materially from actual future events or results. Among the
important factors that could cause actual results to differ
materially from those in any forward-looking statements are (i) our
ability to successfully integrate Fluent into our existing
operations and Fluent's technology and products into our portfolio;
(ii) our ability to sell Fluent's products and further develop
Fluent's technology; (iii) our ability to successfully manage
partner and customer relationships in the single-cell market; (iv)
our ability to manufacture robust instrumentation and consumables,
including Fluent's products; (v) the future conduct and growth of
the business and the markets in which we operate, including the
single-cell market; and (vi) challenges inherent in developing,
manufacturing, and launching new products and services, together
with other factors detailed in our filings with the Securities and
Exchange Commission, including our most recent filings on Forms
10-K and 10-Q, or in information disclosed in public conference
calls, the date and time of which are released beforehand. We
undertake no obligation, and do not intend, to update these
forward-looking statements, to review or confirm analysts'
expectations, or to provide interim reports or updates on the
progress of the current quarter.
About Illumina
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as a global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical, and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture, and other emerging segments. To
learn more, visit illumina.com and connect with us on X, Facebook,
LinkedIn, Instagram, TikTok, and YouTube.
Contacts
Investors:
Salli Schwartz
858-291-6421
IR@illumina.com
Media:
Bonny Fowler
Samantha Beal
PR@illumina.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/illumina-acquires-fluent-biosciences-to-accelerate-single-cell-analysis-and-discovery-to-a-broader-customer-base-302192516.html
SOURCE Illumina, Inc.